Navigation Links
Boston Scientific Receives Industry's First FDA Approval for Drug-Eluting Coronary Stent Use in Heart Attack Patients
Date:2/22/2012

Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, markets for our products, product performance and acceptance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... and MENLO PARK, Calif. , ... Inc. (OTCQB: DMPI) ("DelMar" "the Company") today announced ... statements.  The Company recently changed its fiscal year end ... to list its common stock on a national securities ... financial statements as filed with the United States Securities ...
(Date:8/29/2014)... AMSTERDAM , August 29, 2014 ... invited to participate in the inaugural Tweetchat taking ... CPhI Worldwide , organised by UBM ... October 2014. #CPhIChat is a first of its ... media working across the supply chain, aimed to ...
(Date:8/28/2014)... 2014  Rigrodsky & Long, P.A.: , Do ... LCI )? , Did you purchase your shares ... 16, 2014, inclusive? , Did you lose money in ... want to discuss your rights? Rigrodsky ... Timothy J. MacFall , announces that a complaint has been ...
Breaking Medicine Technology:DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... March 31, 2011 Reportlinker.com announces that ... in its catalogue: Gout ... Therapies such as Krystexxa, Uloric, Adenuric and ... http://www.reportlinker.com/p0464105/Gout-Therapeutics-Market-to-2017--Entry-of-Novel-Therapies-such-as-Krystexxa-Uloric-Adenuric-and-Colcrys-to-Drive-Market.html Gout Therapeutics ...
... that a new market research report is available in ... Testing Markets http://www.reportlinker.com/p089570/Cardiac-Marker-Diagnostic-Testing-Markets.html ... is to describe the specific market segment of the ... testing. This study examines clinical measurement devices and their ...
Cached Medicine Technology:Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 2Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 3Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 4Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 5Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 6Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 7Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 8Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 9Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 10Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 11Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 12Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 2Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 3Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 4Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 5Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 6Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 7Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 8
(Date:8/30/2014)... is a common problem millions of American cope with every day. ... nuisance, for some, it can have a crippling impact on social ... dramatic mood swings and depression. , Those struggling with acne ... In some cases, that can make the problem even worse. Instead ... a quest for clearer skin can now view acne treatment ...
(Date:8/30/2014)... Manhattan Beach, Calif. (PRWEB) August 30, 2014 ... Carol Francis helps listeners understand how they unknowingly developed insomnia ... and have restful nights during. Tune in to the ... . The show airs live on August 30, and ... For more information on programming, go to DrCarolFrancisTalkRadio.com. ...
(Date:8/30/2014)... Hastings and Hastings, a qualified team of knowledgeable ... pleased to report having saved a client $67,100 on ... cases where Hastings and Hastings has tailored its fees ... portion of their settlement or recovery. The firm has ... for Arizona car accident victims is achievable through dedicated ...
(Date:8/30/2014)... "My niece developed a nighttime fever, and ... her fever might get worse," said an inventor from ... of how she was doing, I developed this monitoring ... monitor a child's temperature. The unit instantly alerts parents ... prompt medical care can be given, which is designed ...
(Date:8/30/2014)... 30, 2014 "I had a handicapped friend ... crutches," said an inventor from Wetumpka, Ala. "In order to ... of the shore, I came up with a way for ... created a prototype for the patent-pending Deezers to allow crutches ... individual to use crutches, walkers, or canes at the beach. ...
Breaking Medicine News(10 mins):Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2
... Recommend Photochromic Lenses to Protect Eyes This Summer and ... Throughout the ... the dangers of extended sun exposure and its effects on the skin, ... survey conducted by,the New England Eye Institute and Transitions Optical found that ...
... to vote soon on legislation that would cut ... WASHINGTON, July 9 Seniors across Texas ... Advantage program in,legislation being considered in the U.S. ... from the Medicare Advantage program in Texas,alone and ...
... Additional Research Warranted on Impact of Medicare Modernization ... Shows Possibility of,Longer Wait Times for Patients in ... to a new study,released today in the July ... (JAMA), cancer patients experienced no major changes in ...
... 2006, a pneumococcal vaccine (Prevenar) was introduced in the ... experiences have been published in the journal Vaccine ... pneumococcal infections among young children. , Pneumococcus is ... young children, e.g. meningitis, blood poisoning and pneumonia. Most ...
... lumpectomy linked to depression, fear, study finds , , WEDNESDAY, ... who opt for breast-conserving cancer surgery say they now ... their quality of life, a new study says. , ... were twice as likely to fear their cancer returning ...
... Razadyne ER,from Tier 2 to Tier 3 When Generic Razadyne ... ... WALTHAM, Mass., July 9 Decision Resources, one of ... finds that the generic availability of,Shire/Janssen/Ortho McNeil,s Razadyne (galantamine) in ...
Cached Medicine News:Health News:Study Confirms Americans Place Their Vision at Risk Year Round 2Health News:Study Confirms Americans Place Their Vision at Risk Year Round 3Health News:Texas Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Global Access Project (GAP) Study Examining Patients' Access to Cancer Care Featured in the Journal of the American Medical Association (JAMA) 2Health News:Vaccinated infants well-protected against severe pneumococcal infection in Norway 2Health News:Breast-Conserving Surgery Leaves Many Cancer Patients Disappointed 2Health News:Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008 2Health News:Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli...
For the qualitative detection of antibodies to Treponema pallidum in human serum, plasma and whole blood specimens...
Medicine Products: